Moderna (MRNA) Q2 2025 10-Q Quarterly Report
Filed: Aug 1, 2025Period ending Jun 30, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR Moderna (MRNA) 10-Q quarterly report for Q2 2025, filed with SEC EDGAR on Aug 1, 2025 for the fiscal period ending Jun 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Moderna Q2 2025 10-Q Analysis
Risk Factors
- • New patent infringement lawsuits by GSK filed July 2025 in Unified Patent Court covering Spikevax and mRESVIA RNA delivery technology
- • Updated patent risk: Arbutus lawsuit trial rescheduled to March 9, 2026, impacting COVID vaccine manufacture and sales
- • Most impactful legal risk: Pending Alnylam case in U.S. District Court concerning cationic lipid patents after Federal Circuit ruling favoring Moderna
- • Operational risk: Potential injunctions from European patent claims by GSK could disrupt Spikevax and mRESVIA supply across multiple countries
- • Financial risk: Litigation-related monetary damages sought by GSK and others could materially affect cash flow and earnings
Moderna Q2 2025 Quarterly FinancialsXBRL
Revenue
$142M
▼ -41.1% YoY▲ +31.5% QoQ
Net Income
-$825M
▲ +35.5% YoY▲ +15.0% QoQ
Operating Margin
-638.7%
▼ -7317bp YoY▲ +33349bp QoQ
Net Margin
-581.0%
▼ -5028bp YoY▲ +31809bp QoQ
EPS (Diluted)
$-2.12
▲ +36.5% YoY▲ +15.9% QoQ
Operating Cash Flow
-$919M
▲ +27.9% YoY▲ +11.4% QoQ
Source: XBRL data from Moderna Q2 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Moderna Quarterly Reports
Get deeper insights on Moderna
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.